Inovio reports long-term positive results for COVID-19 vaccine

By The Science Advisory Board staff writers

July 30, 2020 -- Inovio released results of a nonhuman primate study for its COVID-19 DNA vaccine, INO-4800. The vaccine protected the animals 13 weeks after vaccinations and mediated T- and B-cell immune responses, according to the firm.

The results, published on bioRxiv, demonstrated that INO-4800 reduced viral load in the lungs and nasal passages of macaques that received two doses of INO-4800 (one mg) four weeks apart followed by live virus challenge 13 weeks after the second dose.

The vaccinated macaques demonstrated seroconversion after a single dose, with neutralizing antibodies and T cells found in their blood more than four months after the initial dose. Moreover, the levels of antibodies were similar to or greater than those who have recovered from COVID-19. The study showed that the vaccine induced acute and memory T- and B-cell responses, including neutralizing antibodies against the early virus strain as well as the now dominant G614 variant.

The company anticipates beginning phase II/III efficacy trials this summer. A separate nonhuman primate study evaluating the durability of INO-4800 at 12 months postvaccination is currently underway and is supported by the federal government's Operation Warp Speed to accelerate development of a vaccine for SARS-CoV-2.

Inovio vaccine proves potent against SARS-CoV-2 in preclinical trials
Inovio announced that preclinical data for its INO-4800 vaccine candidate were published in Nature Communications on May 20. The results suggesting...
NIH leadership discusses COVID-19 vaccine collaborations
Public-private partnerships could help meet the unprecedented need to manufacture and distribute safe and effective COVID-19 vaccines around the globe,...
Inovio expands manufacturing for COVID-19 vaccine
Inovio has partnered with German contract manufacturer Richter-Helm BioLogics to produce large-scale quantities of Inovio's investigational DNA vaccine.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter